Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)

Trial Profile

Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Rapastinel (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions
  • Sponsors Allergan; Naurex
  • Most Recent Events

    • 03 Oct 2017 Planned End Date changed from 1 Dec 2017 to 15 Oct 2019.
    • 03 Oct 2017 Planned primary completion date changed from 1 Dec 2017 to 15 Oct 2019.
    • 20 Jul 2015 Status changed from not yet recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top